Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;155(1):75e-85e.
doi: 10.1097/PRS.0000000000011485. Epub 2024 Apr 23.

A Ropivacaine-Eluting Poly(Lactide-Co-Caprolactone) Wound Dressing Provided Enhanced Analgesia in Partial-Thickness Porcine Injuries

Affiliations

A Ropivacaine-Eluting Poly(Lactide-Co-Caprolactone) Wound Dressing Provided Enhanced Analgesia in Partial-Thickness Porcine Injuries

Stefan Niederauer et al. Plast Reconstr Surg. .

Abstract

Background: Partial-thickness skin wounds are some of the most painful injuries because of large areas of exposed nerve endings. These injuries often require systemic opioid treatment to manage pain adequately. However, the Centers for Disease Control and Prevention reported nearly 17,000 prescription opioid-related deaths in the United States in 2021 alone, highlighting the ongoing need for nonopioid treatment strategies. The authors developed a novel single-application ropivacaine-eluting primary wound dressing that could provide sustained ropivacaine delivery to partial-thickness wounds and assessed its in vivo feasibility for prolonged nonopioid analgesia.

Methods: Sustained release of ropivacaine from a poly(lactide-co-caprolactone) matrix was first optimized in vitro using dissolution testing and a Box Behnken design of experiments. The optimized dressing was then tested against a clinical control silicone dressing in a porcine partial-thickness wound study to assess analgesic effect, pharmacokinetics, and wound healing.

Results: The ropivacaine-eluting dressing showed a moderate analgesic effect in vivo, where normalized single pinprick scores significantly improved pain over the testing period (4 to 168 hours) (control versus treatment: 232 ± 25% versus 145 ± 16%; P < 0.0003). Ropivacaine blood plasma levels peaked at 8 hours after treatment, with a maximum concentration of 246 ± 74 ng/mL. No significant differences in wound healing were found when compared with control.

Conclusion: The ropivacaine-loaded poly(lactide-co-caprolactone)-based wound dressing provided sustained delivery of ropivacaine to partial-thickness skin wounds and enhanced analgesic effect compared with a clinical standard control dressing.

Clinical relevance statement: This article describes the development and porcine testing of an analgesic wound dressing for management of acute pain in partial-thickness dermal wounds.

PubMed Disclaimer

References

    1. Serebrakian AT, Pickrell BB, Varon DE, et al. Meta-analysis and systematic review of skin graft donor-site dressings with future guidelines. Plast Reconstr Surg Glob Open 2018;6:e1928.
    1. McDermott KW, Weiss AJ, Elixhauser A. Burn-Related Hospital Inpatient Stays and Emergency Department Visits, 2013. Agency for Healthcare Research and Quality; 2006.
    1. Singer DD, Thode HC, Sandoval S, Singer AJ. 465 Time trends and disparities in burn related ED visits 2000–2014: a national perspective. J Burn Care Res. 2018;39:S205–S205.
    1. Centers for Disease Control and Prevention. National Hospital Ambulatory Medical Care Survey: 2017 emergency department summary tables. US Department of Health and Human Services; 2020.
    1. Demirtas Y, Yagmur C, Soylemez F, Ozturk N, Demir A. Management of split-thickness skin graft donor site: a prospective clinical trial for comparison of five different dressing materials. Burns 2010;36:999–1005.

LinkOut - more resources